Celea Therapeutics secured $180 million to support a Phase 3 pivotal study for deupirfenidone, an oral small-molecule candidate for idiopathic pulmonary fibrosis (IPF). PureTech Health’s spinout will use the financing to run a head-to-head trial against a standard of care IPF regimen. The pivotal design positions deupirfenidone to compete directly in a market where efficacy and tolerability benchmarks are tightly defined. For investors, the funding provides runway for late-stage execution and potentially accelerates regulatory planning if the program reaches primary endpoints. By focusing on a comparative Phase 3 approach, Celea is aiming to convert prior clinical activity into a clearer value proposition for clinicians and payers confronting IPF’s limited treatment options.